Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
Metrics to compare | SPRINT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRINTPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −9.5x | −0.5x | |
PEG Ratio | 0.01 | −0.20 | 0.00 | |
Price/Book | 16.6x | 6.6x | 2.6x | |
Price / LTM Sales | 1.0x | 42.0x | 3.3x | |
Upside (Analyst Target) | 233.3% | 8.1% | 43.4% | |
Fair Value Upside | Unlock | 6.5% | 7.1% | Unlock |